Eli Lilly And Co's (NYSE: LLY) investigational RNA-directed drug lepodisiran lowered lipoprotein(a) levels in a Phase 1 study. Elevated levels of Lp(a) have been associated with a higher risk of heart disease, heart attack, and stroke.
The results were presented at the American Heart Association's scientific meeting and published in JAMA.
The trial enrolled 48 participants without cardiovascular disease and with lipoprotein(a) concentrations of 75 nmol/L or greater (or ≥30 mg/dL). A single serious adverse event occurred.
The maximal median change from baseline in serum lipoprotein(a) concentrations was −5% in the placebo group, −41% in the 4 mg of lepodisiran group, −59% in the 12-mg dose group, −76% in the 32-mg dose group, −90% in the 96-mg dose group, −96% ...